Endacea Home Page
Endacea is a development stage biopharmaceutical company with a proprietary A1 adenosine receptor based technology platform for the treatment of asthma, ischemia-reperfusion organ injury, and Gram-negative septicemia (endotoxemia), as well as an assay for
adenosine, A1AR, inflammation, anti-inflammatory, endotoxin, endotoxemia, septicemia, sepsis, asthma, ischemia, reperfusion, ischemia-reperfusion, P2x, purinoceptor, Gram-negative, fibrosis, sclerosis, myocardial, infarction, purine, COPD, autoimmune
Is this your site? Certify your site and update informations
